Ticker League

EBITDA for Vertex Pharmaceuticals (VRTX)

Latest filings through · Reported

Metric

TTM

$5.33B

YoY change

+900.1%

5Y CAGR

+8.2%

Peak year (2025)

$4.86B

EBITDA history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: $4.86B

EBITDA growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: +900.1%

EBITDA history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

  • 2025$4.86B+900.1%
  • 2024$486.30M-89.4%
  • 2023$4.61B+3.8%
  • 2022$4.44B+52.0%
  • 2021$2.92B-11.2%
  • 2020$3.28B+110.5%
  • 2019$1.56B+120.8%
  • 2018$706.78M+584.5%
  • 2017$103.26M+36.8%
  • 2016$75.46M-118.3%
  • 2015−$411.25M-31.3%
  • 2014−$598.75M+7.9%
  • 2013−$554.75M-1406.4%
  • 2012$42.46M-68.3%
  • 2011$133.94M-119.0%
  • 2010−$704.89M+17.7%
  • 2009−$598.88M+40.5%
  • 2008−$426.19M+10.6%
  • 2007−$385.21M+93.1%
  • 2006−$199.52M+74.3%
  • 2005−$114.45M+6.4%
  • 2004−$107.59M-59.3%
  • 2003−$264.53M+115.0%
  • 2002−$123.05M+26.7%
  • 2001−$97.14M+294.0%
  • 2000−$24.65M-44.4%
  • 1999−$44.30M+2.5%
  • 1998−$43.20M+176.9%
  • 1997−$15.60M-57.0%
  • 1996−$36.30M+59.2%
  • 1995−$22.80M+32.6%
  • 1994−$17.20M-437.3%
  • 1993$5.10M-170.8%
  • 1992−$7.20M+89.5%
  • 1991−$3.80M-7.3%
  • 1990−$4.10M—

EBITDA values are taken from Vertex Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Vertex Pharmaceuticals (VRTX)

According to Vertex Pharmaceuticals's latest reported financial statements, the company's current EBITDA (TTM) is $5.33B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported EBITDA of $4.86B – surged 900.1% year-over-year.

Across 2020–2025 (5 years), Vertex Pharmaceuticals EBITDA produced a CAGR of +8.2% – with mixed annual results across the window.

The highest annual EBITDA of $4.86B was reported in 2025. The lowest in the available history was −$704.89M in 2010.

Vertex Pharmaceuticals EBITDA by Year

Vertex Pharmaceuticals EBITDA 2025: $4.86B

Vertex Pharmaceuticals posted EBITDA of $4.86B in 2025, surged 900.1% from 2024. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals EBITDA 2024: $486.30M

In 2024, Vertex Pharmaceuticals reported EBITDA of $486.30M, plunged 89.4% below 2023.

Vertex Pharmaceuticals EBITDA 2023: $4.61B

Vertex Pharmaceuticals EBITDA in 2023 was $4.61B, edged up 3.8% from 2022.

Vertex Pharmaceuticals EBITDA 2022: $4.44B

2022's EBITDA for Vertex Pharmaceuticals came in at $4.44B, surged 52.0% from 2021.

Vertex Pharmaceuticals EBITDA 2021: $2.92B

Vertex Pharmaceuticals EBITDA in 2021 was $2.92B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by EBITDA

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest EBITDA

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation